Summary:
The ACCLAIM Study is a clinical trial to test whether abatacept can stop or delay the progression of relapsing-remitting MS. The science behind abatacept is different from other approved treatments for MS.
Qualified Participants Must:
• Be diagnosed with RRMS
•
Be between 18 and 65 years of age
•
Have experienced one or more documented clinical exacerbations in the past year
•
Have one or more Gd-enhanced MRI lesions in the past year
Qualified Participants May Receive:
Study care as well as compensation for time and travel.